Shares of VIVUS (NASDAQ:VVUS) were up nearly 5% yesterday, after the announced a deal with Aetna (NYSE:AET) for a weight loss program for the big insurer's members. It combines both a drug and lifestyle focus for losing weight. This could potentially boost sales of VIVUS' weight loss drug Qsymia, which came to market with a lot of hype but so far has posted meager numbers.
In this video, Motley Fool health care analyst David Williamson discusses the deal, and how beneficial it could be both to VIVUS and Aetna, but he also notes that the obesity drug war that many thought would explode between Qsymia and Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq has ended up in more of a fizzle, with sales lagging expectations across the board. David then points to one competitor that may end up being far more interesting in this space with a drug that may fall right in the sweet spot between safety and efficacy, and why FDA approval for this competitor drug may be just around the corner.
The Best Biotech Play Today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.